There is exactly one FDA-approved peptide drug for chronic pain, and it is not what most people searching for peptides for nerve pain have in mind: ziconotide (Prialt), a synthetic cone snail peptide given by continuous infusion into the spinal fluid through an implanted pump.[2][3] Experimental peptides such as ARA-290 have small trials, and BPC-157 has only rat data for nerve injury.[7][11] For most neuropathic pain, the first treatments are non-peptide medicines whose benefits are real but modest.[1]
This guide grades each option by evidence. It is part of our pain and nerve peptides hub.
Evidence-graded table
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| TCAs, SNRIs, gabapentinoids (not peptides) | FDA-approved / guideline first-line | Modest pain relief across 313 trials[1] | Several approved for neuropathic pain | Not applicable |
| Ziconotide (intrathecal) | FDA-approved for this use | Pain scores improved 53% vs 18% on placebo in cancer or AIDS pain[4] | Approved 2004 for severe chronic pain needing spinal therapy[3] | Not applicable |
| ARA-290 (cibinetide) | Small human studies | Better neuropathy symptom scores in 22 sarcoidosis patients[7] | Not approved | ARA-290 |
| Cebranopadol (non-peptide, acts on peptide receptors) | Human RCTs (acute pain) | Beat placebo in two phase 3 post-surgery trials[10] | Not approved; filing planned | Not applicable |
| BPC-157 | Animal or lab only | Faster sciatic nerve healing in rats[11] | Not approved | BPC-157 |
| Dermorphin | Small human studies (decades old) | Opioid peptide tested for post-surgical pain in the 1980s[13] | Not approved | Dermorphin |
Start with standard nerve pain care
Neuropathic pain comes from damage to nerves, as in diabetic neuropathy, shingles, chemotherapy, spinal nerve compression or injury. The first steps are treating the cause where possible, such as better blood sugar control, and then medicines with trial support.
A 2025 Lancet Neurology meta-analysis of 313 trials and nearly 49,000 adults estimated that for tricyclic antidepressants, about one extra person in every four to five treated gets meaningful relief compared with placebo (number needed to treat 4.6), with gabapentinoids and SNRIs such as duloxetine helping fewer (numbers needed to treat of 8.9 and 7.4). The authors called the benefits modest.[1] Physical therapy, topical treatments, psychological pain programs and nerve stimulation can add to medicines. A pain specialist can help when first-line options fail.
Ziconotide: the approved nerve-pain peptide
Ziconotide is a 25-amino-acid synthetic copy of a toxin from the cone snail Conus magus. It blocks N-type calcium channels that pass pain signals in the spinal cord, and it is not an opioid.[2] FDA approved it in December 2004.[3]
- Who it is for: adults with severe chronic pain for whom spinal (intrathecal) therapy is warranted and who cannot tolerate or did not respond to other treatments, including spinal morphine.[2]
- Evidence: in a JAMA trial of patients with cancer or AIDS pain, pain scores improved 53.1% with ziconotide versus 18.1% with placebo.[4] A slower-titration trial in 220 adults with severe chronic pain showed a smaller but significant benefit (14.7% vs 7.2% at three weeks) and better tolerability than earlier fast-titration trials.[5]
- Risks: a boxed warning for severe psychiatric symptoms and neurological impairment. It is contraindicated with a history of psychosis, and patients need frequent checks for confusion, hallucinations and mood changes.[2] Dizziness, confusion, unsteady walking and memory problems were common in trials.[5]
Researchers are still exploring new uses, for example a small planned study in chemotherapy-induced nerve pain.[6]
Why ziconotide has to go into the spine
Ziconotide shows a basic problem with peptides for nerve pain. Peptides are large, fragile molecules that are broken down in the gut and cross from the blood into the spinal cord poorly. Ziconotide works where pain signals are relayed in the spinal cord, so it has to be delivered straight into the spinal fluid, with an implanted pump and a slow, careful dose increase.[2] Any claim that a peptide taken by mouth, nasal spray or skin injection will calm nerve pain deserves extra skepticism unless a trial backs it up. Our guide to peptide bioavailability explains why delivery matters so much.
ARA-290 (cibinetide): small, promising trials
ARA-290 is an 11-amino-acid peptide based on part of erythropoietin, designed to calm inflammation without stimulating red blood cell production. In a 22-patient double-blind pilot in sarcoidosis with small fiber neuropathy, four weeks of IV ARA-290 improved a neuropathy symptom score versus placebo, though overall pain scores improved similarly in both groups.[7] A later trial found the 4 mg dose increased small nerve fibers in the cornea, a marker of nerve regrowth.[8] It remains investigational; see our ARA-290 profile.
Cebranopadol: not a peptide, but a peptide-receptor drug
Cebranopadol often comes up in peptide discussions because it acts on the receptor for nociceptin, a natural pain-modulating peptide, as well as the mu-opioid receptor. It is a small-molecule drug, not a peptide.[9] Its developer reported that two phase 3 trials, after abdominoplasty and bunion surgery, showed significant pain reduction versus placebo over 48 hours, and said in August 2026 it planned to submit a new drug application to FDA later that year.[10] Those trials studied acute post-surgical pain, not chronic nerve pain.
BPC-157 and dermorphin
BPC-157 improved healing of transected sciatic nerves in rats, by microscopic, electrical and walking measures.[11] No human nerve pain trial exists, and a 2026 systematic review found only 30 people studied for any use.[12] FDA’s compounding safety page notes possible immune reactions and limited safety data.[14] Our BPC-157 clinical trials guide lists the human reports.
Dermorphin is a frog-skin opioid peptide far more potent than morphine in animals. A 1985 trial tested it for post-surgical pain, but it was never developed into an approved medicine.[13] Like other opioids, it carries risks of breathing suppression and dependence. See our dermorphin profile.
Questions for your pain specialist
- What is causing my nerve pain, and can the cause be treated?
- Have I tried the first-line medicines at adequate doses?
- Am I a candidate for a spinal pump or nerve stimulation?
- Are there clinical trials of new treatments I could join?
For recovery after nerve-sparing or orthopedic surgery, see peptides for post-surgery recovery, and for the full roster of approved peptide drugs, our FDA-approved peptides list.
